Global Pharma Firms Announce Trump Drug Pricing Deals

• Major drugmakers including Pfizer, Novo Nordisk, and Eli Lilly agreed to discounts ranging from 50% to 85% on select medications through TrumpRx.gov
• Novo Nordisk's Ozempic and Wegovy prices will drop from $1,000-$1,350 per month to $350, while insulin products will be available at $35 per month
• Companies committed billions in U.S. investments and agreed to launch future drugs at prices comparable to other developed countries; only Regeneron has yet to sign among the 17 companies contacted

Summary: Trump Drug Pricing Deals with Major Pharmaceutical Companies

President Donald Trump has secured agreements with 16 of 17 major pharmaceutical companies to align U.S. prescription drug prices with those in other developed nations, in exchange for three-year tariff exemptions on drug imports. The deals, announced April 2, involve "most-favoured-nation" pricing commitments and direct-to-consumer sales through a new government platform, TrumpRx.gov.

Key Agreements:

Pfizer committed to discounts up to 85% through TrumpRx.gov, with 50% average savings on primary care treatments including rheumatoid arthritis drug Xeljanz.

Novo Nordisk slashed prices on blockbuster weight-loss drugs Ozempic and Wegovy from $1,000-$1,350 to $350 monthly, while offering insulin products at $35/month.

Eli Lilly agreed to cap weight-loss drug Mounjaro at $50/month, with Zepbound priced at $299-$449 and Foundayo at $149/month through its direct platform.

Bristol Myers Squibb will provide blood-thinner Eliquis free to Medicaid beneficiaries and donate over seven tons of active pharmaceutical ingredients.

Other major participants include Johnson & Johnson, AstraZeneca (up to 80% discounts), AbbVie, Gilead Sciences, Merck, Roche, Novartis, Amgen, Sanofi, GSK, Boehringer Ingelheim, and EMD Serono.

Market Implications:

The agreements represent a significant shift in U.S. pharmaceutical pricing, potentially reducing consumer costs by 50-85% on major medications. Companies have pledged billions in U.S. investments and committed to pricing future drugs at parity with developed nations. Only Regeneron among the 17 contacted companies has yet to finalize an agreement. The deals balance drug affordability with protecting pharmaceutical companies from tariffs, though specific financial impacts on company revenues remain unclear.